China Kidney Cancer Therapeutics Market Analysis

China Kidney Cancer Therapeutics Market Analysis


$ 3999

The China Kidney Cancer Therapeutics Market was valued at $505.64 Mn in 2023 and is predicted to grow at a CAGR of 6.36% from 2023 to 2030, to $788.55 Mn by 2030. China Kidney Cancer Therapeutics Market is growing due to Increased Incidence of Kidney Diseases, Demand for Immunotherapies, Government initiatives, and funding. The industry is primarily dominated by players such as Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Dr. Reddy's Laboratories Ltd (India), Sun Pharmaceutical Industries Ltd (India) and Novartis AG (Switzerland).

ID: IN10CNPH350 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Najib Shaikh

Buy Now

China Kidney Cancer Therapeutics Market Executive Summary

China Kidney Cancer Therapeutics Market is at around $505.64 Mn in 2023 and is projected to reach $788.55 Mn in 2030, exhibiting a CAGR of 6.36% during the forecast period.

The emergence of malignant tumors in the kidneys is a characteristic of kidney cancer. Renal cell carcinoma primarily affects the elderly, typically those in their 50s to 70s. Blood in the urine, pain in the back or flanks, an abdominal mass or lump, exhaustion, appetite loss, inadvertent weight loss, and lack of appetite are typical symptoms. The exact cause of kidney cancer is often unknown, although risk factors such as obesity, smoking, high blood pressure, and family history can increase the likelihood of developing the disease. Depending on the stage and severity of the disease, there are a variety of treatment options available, such as immunotherapy, surgery, targeted therapy, and occasionally radiation therapy. Kidney transplantation is the most common type of treatment for persistent renal disease. Kidney cancer is treated by kidney excision surgery when the disease has spread to the point where it needs to be removed.

China is the second largest pharmaceutical market in the world. There are approximately 46,900 new cases of kidney cancer patients in China per year, according to Chinese Society of Clinical Oncology. Even now, there is still a significant disparity in the quality of medical care provided in different parts of China. For the treatment of more complicated ailments, many people from inland regions and rural areas must travel hundreds of kilometers to the provincial capitals or to famous hospitals in Beijing, Shanghai, and Tianjin. A focused ultrasound system has also been approved in China and in Europe for the treatment of kidney cancer. The market is growing due to the Increased Incidence of Kidney Diseases, Demand for Immunotherapies, Government initiatives, and funding. However Regulatory Hurdles, Adverse effects, and High cost of treatment restrict the growth and potential of the market.

Pfizer Inc. (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.) are key players in the China Kidney Cancer Therapeutics Market.

China Kidney Cancer Therapeutics Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Increased Incidence of Kidney Diseases: The increasing incidence of chronic kidney disease is majorly responsible for driving the growth of the kidney cancer drugs market. Changes in lifestyle of people, consumption of tobacco, and unhealthy diet are some factors responsible for increasing the incidence of chronic kidney disease.

Demand for Immunotherapies: By manipulating the immune system, this novel strategy targets and destroys cancerous cells. As immunotherapy strengthens the body's natural defences, it has demonstrated effective results in treating kidney cancer. This gives patients hope, especially when traditional medicines have little or no effect. The approval of MSD's anti-PD-1 medication, KEYTRUDA (pembrolizumab), by the Drug Controller General of India (DCGI) in October 2023 was a significant development.

Government initiatives and funding: Significant market growth is also being driven by government initiatives and funding that are aimed at kidney problems. These kinds of initiatives seek to strengthen public health services, the economy, and disease surveillance. They also seek to increase awareness. In 2015, the Chinese government unveiled a new five-year strategy aimed at achieving "Healthy China 2020" in order to counteract the declining health of its people. With a predicted 30% increase in beds at public hospitals and a 100% increase in beds at private hospitals, this plan advocated for an expansion of the medical infrastructure, particularly private hospitals. Nivolumab, a novel medication for kidney cancer, was introduced in 2022 by the Clinical Hospital of the Faculty of Medicine of Ribeirao Preto in collaboration with Bristol Myers Squibb and the São Paulo Research Foundation.

Market Restraints

Regulatory Hurdles: Regulatory barriers are among the most significant barriers to the renal cancer medication market. Longer approval periods for new medicines are a common result of these strict regulatory procedures, even if they are essential for patient safety and medication efficacy. The market availability of novel medicines is significantly delayed by these processes, which necessitate lengthy clinical trials and intricate documentation requirements.

Adverse effects: The significant adverse effects of the medications used for the treatment of can kidney cancer can hinder the market's expected rate of growth. Rash, fever, and nausea are examples of side effects that could prevent the market from expanding.

High cost of treatment: The high expense of cutting-edge pharmacological therapies and the inequalities in the healthcare system impede the general accessibility and affordability of kidney cancer medications. This restriction makes it difficult for patients to obtain innovative treatments, which could impede market expansion and make it more difficult to address the growing incidence of kidney cancer. A cost-effectiveness study is necessary in order to help policymakers allocate their limited resources more effectively, as seen by the rising expenses associated with cancer treatment.

Regulatory Landscape and Reimbursement Scenario

China's health insurance program will be supervised by the Health Security Administration (HSA). In addition to centralizing the purchase of drugs and medical devices, the HSA will control medication prices and reimbursement guidelines. All imported medications and medical devices must register or undergo a notification filing process with the National Medical Products Administration (NMPA, formerly known as CFDA) before being marketed or distributed in the Chinese market. Good Clinical Practice (GCP), Good Manufacturing Practices (GMP) abroad, the "Generic Drugs Quality Consistency Evaluation" (GQCE), and the validation of pharmaceutical manufacturing procedures have been in place to in order to monitor production of generics.

China's healthcare system has advanced significantly in recent years, and in order to achieve even greater progress, many parts of the current medical care system are still being examined.

The healthcare insurance system established by the Chinese government provides benefits to approximately 1.36 Bn people and covers about 96% of the population. Additionally, there is a large array of private healthcare solutions accessible, and it is possible to add private insurance to public health insurance.

Competitive Landscape

Key Players

Here are some of the major key players in the China Kidney Cancer Therapeutics Market:

  • Pfizer Inc (U.S.)
  • AstraZeneca (U.K.)
  • Bristol-Myers Squibb Company (U.S.)
  • Dr. Reddy's Laboratories Ltd (India)
  • Sun Pharmaceutical Industries Ltd (India)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Abbott (U.S.)

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

China Kidney Cancer Therapeutics Market Segmentation

Type

  • Renal Cell Carcinoma (RCC)
  • Papillary Renal Cell Carcinoma
  • Chromophobe Renal Cell Carcinoma
  • Unclassified Renal Cell Carcinoma
  • Transitional Cell Carcinoma
  • Wilms Tumor (Nephroblastoma)
  • Renal Sarcoma
  • Angiomyolipoma
  • Oncocytoma
  • Others

By Drug Class

  • Monoclonal Antibodies
  • Trastuzumab
  • Pertuzumab
  • mTOR Inhibitors
  • Sirolimus
  • Everolimus
  • Temsirolimus
  • Immune Checkpoint Inhibitor
  • Atezolizumab
  • Avelumab
  • Durvalumab
  • Combined Therapies
  • Interleukin-2
  • Alpha-Interferon
  • Others

Drug Type

  • Branded
  • Generic

End User

  • Hospitals
  • Homecare
  • Specialty Clinics

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 16 July 2024
Updated by: Anish Swaminathan

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up